Skip to content
Today
Sections

Product Reports disagree5 publishers 2 min read Published Updated

FTC points to Martin Shkreli's livestreams and stock trades as breaches of a lifetime pharma ban

FTC and seven state attorneys general asked a federal judge to hold Martin Shkreli in contempt for allegedly breaking his 2022 lifetime pharma ban. The filing treats his livestreamed commentary on the industry as a breach alongside his trading.

The Product Desk

Send a correction

FTC alleges Shkreli's trades and streams breach ban How the contempt filing reaches Shkreli: what the ban bars, the trades and livestreams the FTC cites, and the fine and penalties sought.

Seven states from the 2020 Daraprim suit join the FTC. The ban bars pharma stock and statements that could influence a company's business. The FTC alleges trades in at least 60 pharma companies' stocks and livestream short campaigns; it seeks a profits fine and escalating penalties.

FTC alleges Shkreli's trades and streams breach ban
WhoHowKindClaim
Seven statesThe same states that joined the FTC in suing Shkreli in 2020 over the Daraprim schemeprecedent9
The banPer FTC and states, bars owning pharma stock and statements that could influence a company's businessconstraint10
Shkreli's tradingFTC alleges he has publicly traded stocks of at least 60 pharma companies since his releaseexposure3
Shkreli's livestreamsFTC alleges he used them to wage public campaigns to short certain pharma company stocksexposure5
Shkreli's trading profitsProposed fine equals his pharma trading profits plus prejudgment interest, no offset for lossescost7
Future violationsFTC and states seek clear and escalating consequences, including incarcerationdecision6

What happened

  • The seven states are New York, California, Illinois, North Carolina, Ohio, Pennsylvania and Virginia, the same ones that joined the FTC's 2020 suit over Daraprim.
  • The FTC alleges that since his release Shkreli has publicly traded stocks of at least 60 pharmaceutical companies and broadcast his opinions on the business and management of many of them.
  • Ars Technica reports that the FTC and the states say he has broken the ban "flagrantly and repeatedly" for nearly the entire time it has applied.
  • They want him to divest from all pharmaceutical companies, pay a fine equal to his trading profits, and face escalating consequences for future violations, including incarceration.
  • Shkreli did not immediately respond to questions Gizmodo emailed on Tuesday.

Why it matters

  • What it limits constraint Enforcing a ban with one limb on holdings and one on public statements takes two records: trades and broadcasts. A team that holds only one of them sees only part of the breach.
  • What it costs cost The proposed fine is measured on trading profits plus prejudgment interest with no credit for losing trades, so Shkreli's exposure follows his winning trades, whatever his net result.
  • What it sets up precedent If the judge grants the escalating-consequences request, any later breach would be answered under penalties set in advance, including incarceration.

According to the FTC, Martin Shkreli said on one of his livestreams: "I'm showing you how to trade and invest in biotech." [4] Shkreli pitched the stream as trading instruction; the FTC alleges he used his livestreams "to wage multiple public campaigns to short certain pharmaceutical company stocks based on his prediction that their key clinical trials would fail." [5]

The order he is accused of breaking has two limbs. The FTC and the states say it "explicitly prohibits" Shkreli from owning stock in pharmaceutical companies and from making public statements that could influence a pharmaceutical company's business. [10] The court that imposed it in 2022 said his "egregious, deliberate, repetitive, long-running, and ultimately dangerous illegal conduct" warranted an injunction of that scope. [11]

The order, as the FTC and states describe it, lists statements that could influence a company's business as an item separate from owning stock, so the streams are at issue on their own, apart from the trades. [10]

"Today's action should serve as notice that the FTC will not hesitate to enforce violations of court orders," said Daniel Guarnera, Director of the FTC's Bureau of Competition. [8] These are allegations in a request to the court, and neither report describes a ruling.

The two outlets disagree on where Daraprim's price started. Ars Technica puts it at $17.50 a pill and Gizmodo at $13.50, both ending at $750. [15][16] Ars's phrase "more than 4,000 percent" fits its own figure: $750 over $17.50 is a rise of about 4,190 percent. [13] From $13.50 it would be about 5,460 percent. [14]

For anyone who has to monitor a person or account under a restriction with both limbs, we'd sort on two questions: does the person hold a position in the company, and does the person address an audience about it. Position and audience: review first, because that is the cell where the FTC's short-campaign allegation sits. Position only: review the trade log. Audience only: review the content, since the order here treats influential statements as a separate item from owning stock. Neither: no action. The cost of that sort is that the audience cells need a person to watch or transcribe streams, and the position cells need only a log.

What to watch

  • Shkreli's answer to the court, including whether he disputes that his streams count as statements that could influence a pharmaceutical company's business.
  • Whether the judge adopts the fine formula with no offset for losses, since it fixes the size of his exposure.
  • Whether the court writes specific penalties, including incarceration, into an order for any future violation.

Clarity's read

What the record supports and how the coverage leans. The claims behind it follow.

Reality

Evidence55
Adoption
Not scored
Hype gap+8
Incentives
Not scored
Confidence72

Perspective Coverage

5 publishers
Builder
Builder 5%
Operator
Operator 49%
Investor
Investor 46%
Why these scores

Claim ledger

Ranked by verification strength, evidence, and original report placement.

  1. [1]

    The FTC and the attorneys general of seven states asked a federal judge on Tuesday to hold Martin Shkreli in contempt for alleged violations of his lifetime ban from the pharmaceutical industry, imposed in 2022.

    Reported Supported Source: Ars TechnicaView cited source
  2. [2]

    The FTC and the seven states say Shkreli has 'flagrantly and repeatedly' violated the ban nearly the entire time it has been in place.

    Reported Supported Source: Ars Technica, citing the FTC and the statesView cited source
  3. [3]

    The FTC alleges that since his release Shkreli has been publicly trading in pharmaceutical industry stocks of at least 60 companies and broadcasting online his opinions about the business and management of many pharmaceutical companies.

    Reported Supported Source: Gizmodo, quoting the FTC's allegationsView cited source
  4. [4]

    The FTC quotes Shkreli saying on one of his livestreams: "I'm showing you how to trade and invest in biotech."

    Reported Supported Source: Gizmodo, citing the FTCView cited source
  5. [5]

    The FTC alleges Shkreli 'used his livestreams to wage multiple public campaigns to short certain pharmaceutical company stocks based on his prediction that their key clinical trials would fail.'

    Reported Supported Source: Gizmodo, quoting the FTCView cited source
  6. [6]

    The FTC and the states seek to force Shkreli to divest from all pharmaceutical companies and pay a fine equal to his profits from trading pharmaceutical company stocks, and want the court to set 'clear and escalating consequences' for future violations, including further financial penalties and incarceration.

    Reported Supported Source: Ars Technica, citing the FTC and the statesView cited source
  7. [7]

    The FTC's proposed fine equals his profits from any pharmaceutical company stock trading, plus prejudgment interest, without the ability to account for offsetting losses.

    Reported Supported Source: Gizmodo, citing the FTC press releaseView cited source
  8. [8]

    "Today's action should serve as notice that the FTC will not hesitate to enforce violations of court orders," said Daniel Guarnera, Director of the FTC's Bureau of Competition.

    Reported Supported Source: Gizmodo, quoting Daniel Guarnera of the FTCView cited source
  9. [9]

    The seven states are New York, California, Illinois, North Carolina, Ohio, Pennsylvania and Virginia, the same states that joined the FTC in suing Shkreli in 2020 over the Daraprim scheme.

    Reported Supported Source: Ars TechnicaView cited source
  10. [10]

    According to the FTC and the states, the ban 'explicitly prohibits' Shkreli from owning stock in pharmaceutical companies and making public statements that could influence a pharmaceutical company's business.

    Reported Supported Source: Ars Technica, citing the FTC and the statesView cited source
  11. [11]

    In 2022 the federal court ruled that 'Shkreli's egregious, deliberate, repetitive, long-running, and ultimately dangerous illegal conduct warrants imposition of an injunction of this scope.'

    Reported Supported Source: Ars Technica, quoting the 2022 court rulingView cited source
  12. [12]

    Shkreli did not immediately respond to questions emailed Tuesday.

    Reported Supported Source: GizmodoView cited source
  13. [13]

    A rise from $17.50 to $750 is about 4,190 percent.

    Derived Supported
  14. [14]

    A rise from $13.50 to $750 is about 5,460 percent.

    Derived Supported
  15. [15]

    Ars Technica reports the Daraprim price rose from $17.50 per pill to $750 per pill and describes the increase as more than 4,000 percent.

    Reported Contested Source: Ars TechnicaView cited source
  16. [16]

    Gizmodo reports Shkreli raised the price of Daraprim from $13.50 to $750 a pill.

    Reported Contested Source: GizmodoView cited source

Sources

5 independent publishers whose own reporting we read for this story.

  1. arstechnica.com

    1 article · October 13, 2026

    Martin Shkreli livestreamed himself violating lifetime pharma ban, FTC says
  2. cnbc.com

    1 article · October 14, 2026

    Martin Shkreli
  3. gizmodo.com

    1 article · October 13, 2026

    Pharma Bro Martin Shkreli Could Be in Big Trouble Again
  4. qz.com

    1 article · October 13, 2026

    FTC and 7 states are seeking to hold Martin Shkreli in contempt over pharma ban
  5. statnews.com

    1 article · October 13, 2026

    STAT+: FTC demands Martin Shkreli divest his pharma stocks

Topics and entities

Topics

  • US Regulatory Enforcement Against Big Tech
  • Drug pricing
  • Securities trading restrictions

Entities